

GALLIMUNE 303 ND+IB+ART

Water-in oil emulsion for injection

Not
authorised

- Newcastle disease virus, strain Ulster 2C, Inactivated
- Avian infectious bronchitis virus, type Massachusetts, strain M41, Inactivated
- Turkey rhinotracheitis virus, strain VCO3, Inactivated

Product identification

Medicine name:

GALLIMUNE 303 ND+IB+ART Water-in oil emulsion for injection

GALLIMUNE 303 ND+IB+ART, injekciné emulsija

Active substance:

Newcastle disease virus, strain Ulster 2C, Inactivated

Avian infectious bronchitis virus, type Massachusetts, strain M41, Inactivated

Turkey rhinotracheitis virus, strain VCO3, Inactivated

Target species:

Chicken (for reproduction)

Route of administration:

Intramuscular use

Product details

Active substance and strength:

Newcastle disease virus, strain Ulster 2C, Inactivated

50.00 50% Protective Dose / 0.30 millilitre(s)

Avian infectious bronchitis virus, type Massachusetts, strain M41, Inactivated

18.00 log₁₀ haemagglutination inhibiting unit(s) / 0.30 millilitre(s)

Turkey rhinotracheitis virus, strain VCO3, Inactivated

0.76 interference percentage unit(s) / 0.30 millilitre(s)

Pharmaceutical form:

Emulsion for injection

Withdrawal period by route of administration:

Intramuscular use:

-

Chicken (for reproduction)

- Egg. 0 day

- Meat and offal. 0 day

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QI01AA21

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription except for some pack sizes

Authorisation status:

Surrendered

Authorised in:

Lithuania

Package description:

(ID4): 1 Box with 10 Bottle (PolyPropylene) with 300 millilitre(s) (3000 millilitre(s))

(ID3): 1 Box with 1 Bottle (PolyPropylene) with 300 millilitre(s) (300 millilitre(s))

(ID2): 1 Box with 10 Bottle (PolyPropylene) with 150 millilitre(s) (1500 millilitre(s))
(ID1): 1 Box with 1 Bottle (PolyPropylene) with 150 millilitre(s) (150 millilitre(s))

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Immunological veterinary medicinal product application (Article 13d of Directive No 2001/82/EC)

Marketing authorisation holder:

Boehringer Ingelheim Animal Health France

Marketing authorisation date:

27/07/2004

Manufacturing sites for batch release:

Boehringer Ingelheim Animal Health France

Responsible authority:

State Food And Veterinary Service

Authorisation number:

LT/2/04/1670/001-004

Date of authorisation status change:

28/04/2009

Reference member state:

Germany

Procedure number:

DE/V/0228/001

To consult adverse reactions on veterinary medicinal products please go to
www.adrreports.eu/vet

Documents

Summary of Product Characteristics

RV1670.PDF